University of Hertfordshire

From the same journal

By the same authors

Polymeric gels for intravaginal drug delivery

Research output: Contribution to journalArticlepeer-review

Standard

Polymeric gels for intravaginal drug delivery. / Cook, Michael; Brown, Marc.

In: Journal of Controlled Release, Vol. 270, 28.01.2018, p. 145-157.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{38195f571b634f5e9637b4ba53b6830d,
title = "Polymeric gels for intravaginal drug delivery",
abstract = "Intravaginal drug delivery can elicit a local effect, or deliver drugs systemically without hepatic first pass metabolism. There are a number of emerging areas in intravaginal drug delivery, but the vagina is a challenging route of administration, due to the clearance mechanisms present which result in poor retention of dosage forms, and the potential for irritation and other adverse reactions. Gel formulations are desirable due to the ease of application, spreading and that they cause little to no discomfort to the patient. However, these dosage forms, in particular, are poorly retained and traditional gels typically have little control over drug release rates. This has led to a large number of studies on improving the retention of vaginal gels and modulating the controlled release of drugs from the gel matrix.This review outlines the anatomy and physiology of the vagina, focussing on areas relevant to drug delivery. Medical applications of vaginally administered medicines is then discussed, followed by an overview of polymeric gels in intravaginal drug delivery. The sensorial properties of intravaginal gels, and how these relate to user compliance are also summarised. Finally, some important barriers to marketing approval are described.",
keywords = "Clinical trials, HIV PrEP, In vitro models, Mucoadhesion, Regulatory approval, Thermogelling materials",
author = "Michael Cook and Marc Brown",
note = "This document is the Accepted Manuscript version of the following article: Michael T. Cook, and Marc b. Brown, {\textquoteleft}Polymeric gels for intravaginal drug delivery{\textquoteright}, Journal of Controlled Release, Vol. 270: 145-157, January 2018. Under embargo until 6 December 2018. The final, definitive version is available online at DOI: https://doi.org/10.1016/j.jconrel.2017.12.004 ",
year = "2018",
month = jan,
day = "28",
doi = "10.1016/j.jconrel.2017.12.004",
language = "English",
volume = "270",
pages = "145--157",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Polymeric gels for intravaginal drug delivery

AU - Cook, Michael

AU - Brown, Marc

N1 - This document is the Accepted Manuscript version of the following article: Michael T. Cook, and Marc b. Brown, ‘Polymeric gels for intravaginal drug delivery’, Journal of Controlled Release, Vol. 270: 145-157, January 2018. Under embargo until 6 December 2018. The final, definitive version is available online at DOI: https://doi.org/10.1016/j.jconrel.2017.12.004

PY - 2018/1/28

Y1 - 2018/1/28

N2 - Intravaginal drug delivery can elicit a local effect, or deliver drugs systemically without hepatic first pass metabolism. There are a number of emerging areas in intravaginal drug delivery, but the vagina is a challenging route of administration, due to the clearance mechanisms present which result in poor retention of dosage forms, and the potential for irritation and other adverse reactions. Gel formulations are desirable due to the ease of application, spreading and that they cause little to no discomfort to the patient. However, these dosage forms, in particular, are poorly retained and traditional gels typically have little control over drug release rates. This has led to a large number of studies on improving the retention of vaginal gels and modulating the controlled release of drugs from the gel matrix.This review outlines the anatomy and physiology of the vagina, focussing on areas relevant to drug delivery. Medical applications of vaginally administered medicines is then discussed, followed by an overview of polymeric gels in intravaginal drug delivery. The sensorial properties of intravaginal gels, and how these relate to user compliance are also summarised. Finally, some important barriers to marketing approval are described.

AB - Intravaginal drug delivery can elicit a local effect, or deliver drugs systemically without hepatic first pass metabolism. There are a number of emerging areas in intravaginal drug delivery, but the vagina is a challenging route of administration, due to the clearance mechanisms present which result in poor retention of dosage forms, and the potential for irritation and other adverse reactions. Gel formulations are desirable due to the ease of application, spreading and that they cause little to no discomfort to the patient. However, these dosage forms, in particular, are poorly retained and traditional gels typically have little control over drug release rates. This has led to a large number of studies on improving the retention of vaginal gels and modulating the controlled release of drugs from the gel matrix.This review outlines the anatomy and physiology of the vagina, focussing on areas relevant to drug delivery. Medical applications of vaginally administered medicines is then discussed, followed by an overview of polymeric gels in intravaginal drug delivery. The sensorial properties of intravaginal gels, and how these relate to user compliance are also summarised. Finally, some important barriers to marketing approval are described.

KW - Clinical trials

KW - HIV PrEP

KW - In vitro models

KW - Mucoadhesion

KW - Regulatory approval

KW - Thermogelling materials

UR - http://www.scopus.com/inward/record.url?scp=85037531730&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2017.12.004

DO - 10.1016/j.jconrel.2017.12.004

M3 - Article

VL - 270

SP - 145

EP - 157

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -